Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin

Abstract

Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.

Anagrelide influences thrombotic risk, and prolongs progression‐free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin

“…It builds on the findings of analyses at 6 years, reporting data at 10 years. Study methods are fully reported elsewhere 14 . In brief, a questionnaire based on the 2008 revision of the World Health Organization (WHO) diagnostic criteria 16 was used to collect data on ET patients electronically.…”

“…In 2016, we reported a study of ET management using MPN data taken from a registry created by the Hungarian MPN Working Group (HUMYPRON GROUP) 14 . The HUMYPRON GROUP MPN registry includes patient data on epidemiology, diagnostics, therapeutics and disease complications, 14,15 with data entered online enabling continuing update and searches for association analysis.…”

“…Our first report detailed outcomes of ET patients treated with anagrelide vs hydroxyurea+aspirin followed for (median) 6 years 14 . Significantly fewer minor arterial and minor venous thrombotic events (TEs) were reported in anagrelide‐treated patients vs hydroxyurea+aspirin over 6 years ( P < .001).…”

Philadelphia-negatív krónikus Myeloproliferativ Neoplasia Magyarországi Regiszter. Essentialis thrombocythaemiás betegeink adatainak elemzése

“…A 141 HU + ASA és a 139 anagrelidkezelt beteg TEeseményeinek az eddigi közleményekkel [9,10] való összehasonlítása érdekes, azoktól jelentősen eltérő eredményt mutat [11].…”

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia

“…was not inferiorly effective in the prevention of thrombotic events in comparison with the unspecific cytoreductive compound hydroxyurea in the ANAHYDRET study which included exclusively WHO-classified patients with ET. 5,6 A retrospective analysis of a large anagrelide-treated thrombocythemic MPN patient cohort suggests that both elevated WBC and elevated PLT counts during follow-up are associated with a statistically significant elevated rate of thrombosis. 7 Otherwise, near to normal values of PLT and WBC counts are associated with the lowest rate of thrombosis, whereas lowering of only one parameter is suboptimal when the other parameter is still elevated.…”